NASDAQ$VKTX
Viking Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Viking Therapeutics reported financial results for the first quarter ended March 31, 2021.
Viking Therapeutics reported a net loss of $14.0 million, or $0.19 per share, for the first quarter ended March 31, 2021. The company's cash, cash equivalents, and short-term investments totaled $241.7 million at the end of the quarter.
- U.S. and European sites continue to enroll Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.
- Phase 1 study evaluating VK0214 in healthy volunteers is ongoing; the company expects to initiate a proof-of-concept trial in X-ALD patients mid-2021.
- Viking completed the first quarter of 2021 with $241.7 million in cash, cash equivalents and short-term investments.
- The company remains on track to complete enrollment in the VOYAGE trial in the second half of 2021.
Headline financials
Revenue & EPS history
Viking Therapeutics · Revenue · Quarterly
$0
Forward guidance
Viking Therapeutics is focused on the development of novel therapies for metabolic and endocrine disorders.
Tailwinds
- Enrollment continues in Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.
- VK2809 has demonstrated promising therapeutic potential in a range of lipid disorders.
- Phase 1 study evaluating VK0214 in healthy volunteers is ongoing.
- VK0214 is being evaluated as a potential treatment for X-linked adrenoleukodystrophy (X-ALD).
- Strong balance sheet provides runway to complete multiple key clinical milestones.
Headwinds
- Risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials
- Risks that prior clinical and preclinical results may not be replicated
- Risks regarding regulatory requirements
- Risks related to the COVID-19 pandemic
- Viking disclaims any obligation to update these forward-looking statements except as required by law.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+1.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+10.3%
Avg return
30 days after
48%
21 / 44 earnings
Positive
+25.5%
Q2 2024
Best reaction
-12.1%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | -0.1% | +4.4% | |
| Q4 2025 | +6.8% | +6.7% | +24.8% | |
| Q3 2025 | +8.1% | +11.2% | +9.0% | |
| Q1 2025 | -0.5% | +8.3% | +4.6% | |
| Q4 2024 | -6.1% | -10.6% | -13.1% | |
| Q3 2024 | +18.0% | +20.1% | -15.2% | |
| Q2 2024 | +25.5% | +18.8% | +25.4% | |
| Q1 2024 | +6.1% | +16.2% | -3.4% | |
| Q4 2023 | +17.4% | +28.9% | +191.7% | |
| Q3 2023 | -9.2% | -10.0% | +15.3% | |
| Q2 2023 | -5.4% | +0.1% | -6.0% | |
| Q1 2023 | -1.4% | +11.3% | +7.2% | |
| Q4 2022 | +7.2% | +6.7% | +3.9% | |
| Q3 2022 | -1.5% | +0.2% | -2.0% | |
| Q2 2022 | -2.1% | -12.0% | +2.1% | |
| Q1 2022 | +5.7% | +10.5% | +1.7% | |
| Q4 2021 | +12.8% | +4.5% | -11.4% | |
| Q3 2021 | +5.5% | +3.0% | -22.9% | |
| Q2 2021 | +6.5% | +6.5% | +9.5% | |
| Q1 2021 | +0.5% | +0.3% | -15.9% | |
| Q4 2020 | -11.1% | -15.2% | -25.7% | |
| Q3 2020 | +0.2% | +0.4% | +19.9% | |
| Q2 2020 | +14.4% | +10.8% | +3.6% | |
| Q1 2020 | -12.1% | +7.9% | +15.3% | |
| Q4 2019 | -6.4% | -4.4% | -28.9% | |
| Q3 2019 | +12.0% | +19.8% | +6.0% | |
| Q2 2019 | -5.9% | -6.0% | -9.6% | |
| Q1 2019 | +7.9% | +6.2% | -1.9% | |
| Q4 2018 | -3.3% | +6.5% | +17.2% | |
| Q3 2018 | -4.4% | -14.6% | -29.9% | |
| Q2 2018 | -0.2% | +3.0% | +8.6% | |
| Q1 2018 | +9.8% | +10.0% | +133.4% | |
| Q4 2017 | -7.1% | -0.2% | -27.2% | |
| Q3 2017 | -5.2% | +16.9% | +76.6% | |
| Q2 2017 | +6.3% | +8.4% | +21.1% | |
| Q1 2017 | -5.1% | -9.4% | -8.7% | |
| Q4 2016 | -7.8% | -7.8% | +6.2% | |
| Q3 2016 | +10.0% | +18.0% | +12.0% | |
| Q2 2016 | -3.8% | -3.8% | +2.3% | |
| Q1 2016 | +5.9% | — | — | |
| Q4 2015 | -10.7% | — | — | |
| Q3 2015 | -9.9% | — | — | |
| Q2 2015 | +5.7% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro